Ganglioside GM1, monosialotetrahexosylganglioside, stroke
Ganglioside GM1 is a member of the ganglioside family which has been used in many countries and is thought of as a promising alternative treatment for preventing several neurological diseases, including cerebral ischemic injury. The therapeutic effects of GM1 have been proved both in neonates and in adults following ischemic brain damage; however, its clinical efficacy in patients with ischemic stroke is still uncertain. This review examines the recent knowledge of the neuroprotective properties of GM1 in ischemic stroke, collected in the past two decades. We conclude that GM1 may have potential for stroke treatment, although we need to be cautious in respect of its complications.
Digital Object Identifier (DOI)
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License
Citation / Publisher Attribution
Cell Transplantation, v. 28, issue 6, p. 657-661
Scholar Commons Citation
Zhang, Wenchao; Krafft, Paul R.; Wang, Tianlong; Zhang, John H.; Li, Li; and Tang, Jiping, "Pathophysiology of Ganglioside GM1 in Ischemic Stroke: Ganglioside GM1: A Critical Review" (2019). Neurosurgery and Brain Repair Faculty Publications. 44.
Was this content written or created while at USF?